The ever changing directions of big pharma, both are looking for somewhat the same result, business and profit, just 2 different ways to hopefully attain it. BD
Procter & Gamble Eyes Exit From Prescription Drugs
Procter & Gamble sells about $2 billion worth of prescription drugs every year, but you probably don’t think of P&G as a pharma company. As it turns out, neither does P&G.
The company has hired Goldman Sachs to look for potential buyers for its prescription drugs business the FT reports.
P&G sells the osteoporosis drug Actonel, and comarkets the overactive bladder drug Enablex with Novartis.
The company’s CEO recently told analysts that P&G invested in pharma in the ’90s, when drug companies were riding high, the FT notes. But in this era, when safe, stable consumer products are the place to be, the pharma sideline makes less sense.
AstraZeneca: One Pharma Giant Not Looking for a Big Deal
Pfizer made the big deal, Roche wants one and Merck and Sanofi-Aventis won’t rule it out. But AstraZeneca isn’t in the market.
As the Economist notes in a story this week, the company’s CEO David Brennan (pictured) recently said it doesn’t “need a merger or significant acquisition.”
Like the rest of the industry, AZN is cutting lots of jobs and gearing up for more generic competition.
The company has been among the most aggressive in the industry in shifting to production to China, and has recently set up a research center outside of Shanghai.
0 comments :
Post a Comment